Outset Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OM research report →
Range $7 – $15
Price Chart
About the company
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes.
- CEO
- Leslie L. Trigg
- IPO
- 2020
- Employees
- 310
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on OM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $52.97M
- P/E
- -0.73
- PEG
- -0.01
- P/S
- 0.43
- P/B
- 0.64
- EV/EBITDA
- -2.28
- Div Yield
- 0.00%
- Gross Margin
- 42.04%
- Op Margin
- -51.24%
- Net Margin
- -58.33%
- ROE
- -68.03%
- ROIC
- -33.19%
Latest fiscal year · YoY change
- Revenue
- $119.48M+5.1%
- Gross Profit
- $46.75M+21.2%
- Op Income
- $-66,714,000
- Net Income
- $-81,653,000+36.2%
- EPS
- $-5.37+85.5%
- OCF Growth
- +60.2%
- FCF Growth
- +59.8%
- 52W High
- $6.49
- 52W Low
- $2.77
- 50D MA
- $3.72
- 200D MA
- $4.05
- Beta
- 1.92
- RSI (14)
- 28
- Avg Volume
- 140.40K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Outset Medical delivered 14% revenue growth in Q3 2026, improved gross margin, and reiterated full-year guidance while highlighting refresh, expansion, and home-dialysis tailwinds.· November 4, 2026
- Revenue was $33.6 million, up 14% year over year and 6% sequentially, with growth across consoles, consumables, and service.
- Non-GAAP gross margin improved to 40.8%, up about 100 basis points, driven by product cost improvements, lower overhead, and service efficiencies.
- The company pointed to three console growth drivers: refresh sales, expansion within existing customers, and new-customer adoption.
- Management emphasized strong customer advocacy, including 96% cumulative retention among parent console customers and satisfaction scores above the consulting firm’s healthcare benchmarks.
- Outset reiterated 2026 revenue guidance of $125 million to $130 million and expects full-year non-GAAP gross margin in the low-40% to mid-40% range.
Third-quarter 2026 revenue was $33.6 million, up 14% year over year and 6% sequentially. Product revenue was $23.7 million, up 15%; console revenue was $10.5 million, up 26%; consumable revenue was $13.2 million, up 8%; and service and other revenue was $9.9 million, up 12%. Recurring revenue was $23.1 million, up 10% year over year. Non-GAAP gross margin was 40.8%, up about 100 basis points year over year, while product gross margin was 44.2% and service and other gross margin was 32.4%. Non-GAAP operating expenses were $24.2 million, with non-GAAP net loss of $12.9 million versus $12.4 million a year ago. The company ended the quarter with $140.7 million in cash, cash equivalents, short-term investments, and restricted cash, and cash use was $10.3 million in the quarter. Outset reiterated full-year 2026 revenue guidance of $125 million to $130 million and expects non-GAAP gross margin in the low-40% to mid-40% range, noting that a higher mix of console sales could pressure the range toward the lower end.
Leslie Trigg said the quarter reflected strong execution across implementation, expansion, refresh, and next-generation product preparation. She framed the business around three growth drivers: a refresh opportunity of over 3,000 consoles and about $150 million over the next several years, expansion within existing accounts, and white-space hospital adoption. Her tone was optimistic but measured, stressing that the company is prioritizing a high-quality customer experience as it works toward broader rollout of next-gen Tablo and deeper penetration of the top 250 health systems.
Renee Gaeta highlighted the quarter’s financial progress, including $33.6 million in revenue, 40.8% non-GAAP gross margin, and 300+ basis points of operating leverage. She said gross margin benefited from product cost improvements, reduced overhead, and service efficiencies, while service and other gross margin rose to 32.4% as implementation and EMR attach rates expanded. She also said cash use was $10.3 million in Q3, putting the company on track for about $40 million of cash use for the full year, and reiterated 2026 revenue guidance of $125 million to $130 million and gross margin guidance in the low-40% to mid-40% range.
Analysts focused on the home-dialysis opportunity, the HHS kidney care plan, and whether industry shifts could increase adoption; Leslie said the policy changes could be a positive tailwind but that implementation will determine the ultimate impact. She said Tablo’s home business is supported by fast training and strong retention, citing 90% or greater retention in the first 90 days as a key KPI. On the acute side and next-generation product launch, management said preparations are continuing and that the company is prioritizing a high-quality customer experience over speed, with a broader release expected in the coming months and quarters. When asked why guidance was not raised and about 2027, Renee said the company is sticking to a disciplined guidance approach and will discuss next year in more detail at Q4, while Leslie said they are not seeing major changes in the capital spending climate.
The call pointed to several tangible growth drivers: strong demand from refresh, expansion, and new-customer opportunities; a large installed base that supports recurring revenue; and a policy backdrop that may favor more home dialysis and new technologies. Management also cited 96% cumulative retention among console customers, improving gross margin, and strong customer advocacy as evidence that the business model is gaining traction.
Management did not raise guidance, saying the company prefers a disciplined approach and that the second half of 2026 already has significant growth embedded. Gross margin remains in the low-40% range and could be pressured by a higher mix of console sales, while non-GAAP net loss was still $12.9 million. The next-generation rollout is still in preparation, and management said it is moving deliberately to protect the customer experience rather than pushing for speed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.5%
- Shares Outstanding
- 18.85M
- Float Shares
- 14.60M
of shares held by institutions
95 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 2.74M | ▼ 6.25K |
| Bml Capital Management, LLC | 2.52M | 0 |
| Vanguard Group Inc | 977.97K | ▼ 4.65K |
| Perceptive Advisors LLC | 833.33K | 0 |
| Vanguard Capital Management LLC | 780.13K | 0 |
| Bank Of America Corp | 667.44K | ▲ 1.59K |
| Pfm Health Sciences, LP | 582.12K | 0 |
| Marshall Wace, Llp | 483.38K | ▲ 271.39K |
| Blackrock, Inc. | 366.60K | ▼ 51.61K |
| Aqr Capital Management LLC | 343.06K | ▼ 655.90K |
| Geode Capital Management, LLC | 208.96K | ▲ 4.31K |
| Clayton Partners LLC | 200.00K | ▲ 162.47K |
Held by 45 ETFs
Biggest fund positions in OM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Gaeta Renee | sell | 4,498 |
| Nov 16, 26 | Trigg Leslie | sell | 3,403 |
| Oct 2, 26 | Leonard Braden Michael | buy | 16,575 |
| Oct 1, 26 | Leonard Braden Michael | buy | 228,334 |
| Aug 17, 26 | Trigg Leslie | sell | 3,437 |
| Aug 17, 26 | Brottem John L. | sell | 2,632 |
| Aug 17, 26 | Gaeta Renee | sell | 4,543 |
| Jun 26, 26 | Brottem John L. | other | 59,830 |
| Jun 26, 26 | Gaeta Renee | other | 71,630 |
| Jun 26, 26 | Trigg Leslie | other | 99,160 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OM coverage
Recent articles, reports, and earnings notes.
No research on OM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OM report →All You Need to Know About Outset Medical (OM) Rating Upgrade to Buy
zacks.com · Nov 12
Outset Medical (NASDAQ:OM) Stock Breaks Above 200 Day Moving Average – Here’s What Happened
defenseworld.net · Nov 7
Outset Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
Outset Medical Reports Third Quarter 2026 Results
globenewswire.com · Nov 4
Outset Medical to Participate in the 2026 Stifel Healthcare Conference
globenewswire.com · Oct 27
Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
globenewswire.com · Oct 21
Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock
zacks.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.